The Rosen Law Firm, P.A. announces that it is investigating potential securities claims against Hyperion Therapeutics, Inc. HPTX, -6.22% resulting from allegations that the Company may have issued materially false statements to investors.
On September 8, 2014, Hyperion Therapeutics shocked the market when it announced that it would terminate the development of its diabetes drug, DiaPep277, following the discovery of serious misconduct by some employees of Andromeda Biotech Ltd., a recently acquired subsidiary. Specifically, the misconduct included “collusion with a third-party biostatistics firm in Israel to improperly receive un-blinded DIA-AID 1 trial data and to use such data in order to manipulate the analyses to obtain a favorable result” and the continuing of “the improper practice of sharing and examining un-blinded data from the ongoing DIA-AID 2 trial.” This adverse news caused shares of Hyperion Therapeutics to fall sharply during intraday trading on September 3, 2014, damaging investors.
The Rosen Law Firm is preparing a securities class action lawsuit on behalf of Hyperion Therapeutics investors. If you purchased Hyperion Therapeutics securities on or before September 8, 2014 and would like to recover your losses, please visit the website to join the class action http://rosenlegal.com/cases-350.html. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.